In recent years, there has been an increase in approved monoclonal antibodies for the treatment of a variety of diseases. The complex nature of these larger molecules generates unwanted immunogenicity that targets the therapeutic drug, impacting its safety and efficacy profile. At Altasciences, our technology and bioanalytical methods are constantly evolving to achieve highly sensitive and robust ADA assays. Our scientific experts understand the importance of putting into context the clinical relevance of the study to ensure the success of your drug product. 

In this issue of The Altascientist, see how we overcome the challenges faced when evaluating ADA assays.

Contact our experts to learn more about our large molecule expertise.

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.